Key result
Statins remain the first-choice treatment for heterozygous familial hypercholesterolemia, with several alternative modalities available as add-on or monotherapy for those not reaching targets.
Answers are grounded in this paper and cite their sources.
This review discusses current and alternative treatment options for heterozygous familial hypercholesterolemia, emphasizing statins as first-line therapy.
Heterozygous familial hypercholesterolemia is associated with elevated levels of LDL-cholesterol and the development of premature cardiovascular disease. The condition is considerably under-diagnosed and under-treated. Statins are the first choice treatment for all patients with heterozygous familial hypercholesterolemia. For those patients who do not reach their treatment target or who are unable to use adequate statin dose, several alternative treatment modalities can be used, either as add-on therapy or as monotherapy. In this review the various treatment options are discussed.
No takes yet. Share an insight, caveat, or question.
Huijgen et al. (2008) conducted a review in Heterozygous familial hypercholesterolemia. Statins and alternative treatment modalities was evaluated. Statins remain the first-choice treatment for heterozygous familial hypercholesterolemia, with several alternative modalities available as add-on or monotherapy for those not reaching targets.
Synapse has enriched 10 related papers. Consider them for comparative context: